Nubeqa (Darolutamide)

Darolutamide, the active ingredient in Nubeqa, is an androgen receptor antagonist presented as a tablet for oral use. It treats non‑metastatic castration‑resistant prostate cancer in men who have progressed despite androgen‑deprivation therapy. GNH USA supplies Nubeqa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Nubeqa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nubeqa is indicated for prostate cancer that has progressed on androgen‑deprivation therapy, specifically targeting the non‑metastatic castration‑resistant disease state.

- Non‑metastatic castration‑resistant prostate cancer (nmCRPC): delays radiographic progression and improves overall survival. - High‑risk localized prostate cancer (investigational): being studied as part of combination regimens to reduce recurrence after definitive therapy. - Metastatic castration‑resistant prostate cancer (mCRPC) (off‑label): may be used in clinical practice where physicians consider androgen‑receptor blockade. - Ongoing clinical trials: evaluated in combination with other hormonal agents for broader disease control.

Adverse reactions reported with darolutamide are generally mild to moderate, but clinicians monitor for both common and serious events.

Common Side Effects: - Fatigue: mild to moderate tiredness reported by many patients. - Rash: skin erythema or maculopapular eruptions. - Elevated liver enzymes: increases in ALT or AST. - Hypertension: new‑onset or worsening blood pressure. - Diarrhoea: loose stools, usually self‑limiting. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Seizures: infrequent but reported, particularly in patients with pre‑existing risk factors. - Severe hepatic impairment: marked elevation of liver enzymes or hepatitis. - Cardiovascular events: myocardial infarction or stroke in high‑risk individuals. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Pulmonary embolism: rare thromboembolic events. - Anaphylaxis: rare hypersensitivity reactions.

Before initiating darolutamide, clinicians should evaluate patient history and monitor relevant parameters.

- Liver function: assess baseline ALT/AST and monitor periodically. - Blood pressure: measure regularly, especially in patients with hypertension. - Cardiac risk: evaluate history of cardiovascular disease before use. - Drug interactions: review concomitant medications for CYP2C8/3A4 substrates. - Pregnancy and lactation: contraindicated in women; avoid exposure to fetal tissue. - Store at ambient temperature: keep below 25°C, protect from moisture and light, retain in original packaging.

Darolutamide is metabolised primarily via CYP2C8 and CYP3A4, creating potential for clinically relevant drug interactions.

Major Interactions (Avoid): - Strong CYP2C8 inhibitors (e.g., gemfibrozil) – may increase darolutamide exposure. - Strong CYP3A4 inducers (e.g., rifampicin) – may reduce therapeutic levels. - Anticoagulants (warfarin): heightened bleeding risk due to metabolic competition.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin) – may modestly raise darolutamide concentrations. - Statins metabolised by CYP3A4 (e.g., simvastatin) – monitor for myopathy. - Proton pump inhibitors – may affect absorption, observe clinical response.